Schedule 13D ownership disclosure
Adamis Pharmaceuticals Corp
Security class unavailable · CUSIP: 00547W208
Event date: 2017-09-20
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 4.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001144204-17-049483
- Form type
- SC 13D
- Filer
- DMK PHARMACEUTICALS Corp
- CIK
- CIK 887247
- Filed
- Sep 25, 2017
- Reporting period
- Sep 20, 2017
- Description
- Schedule 13D beneficial ownership